亿帆医药(002019) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥905,920,591.79, a decrease of 24.53% compared to ¥1,200,337,373.23 in the same period last year[2] - Net profit attributable to shareholders was ¥121,266,909.58, down 8.30% from ¥132,244,842.10 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥76,821,416.28, reflecting a significant decline of 31.90% from ¥112,814,160.06 in the previous year[3] - The total profit for Q1 2022 was approximately ¥135.57 million, a decrease of 8.5% compared to ¥147.57 million in Q1 2021[22] - The net profit attributable to the parent company was approximately ¥121.27 million, down from ¥132.24 million, representing a decline of 8.3% year-over-year[22] - The company's net profit for Q1 2022 was CNY 124,239,046.87, a decrease of 7.9% compared to CNY 134,304,706.57 in Q1 2021[21] - The company's total comprehensive income for Q1 2022 was approximately ¥89.54 million, down from ¥114.53 million in Q1 2021, indicating a decline of 21.8%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥46,018,343.12, a drastic decrease of 130.90% compared to ¥148,929,731.56 in the same period last year[4] - The operating cash flow for Q1 2022 was negative at approximately -¥46.02 million, compared to a positive cash flow of ¥148.93 million in the same period last year[23] - Total cash inflow from operating activities was approximately ¥1.01 billion, a decrease of 17.2% from ¥1.22 billion in Q1 2021[23] - The company reported a net cash outflow from investing activities of approximately -¥145.91 million, an improvement from -¥217.93 million in Q1 2021[24] - Cash and cash equivalents at the end of Q1 2022 totaled approximately ¥1.02 billion, slightly down from ¥1.03 billion at the end of Q1 2021[24] - The company's cash and cash equivalents increased to CNY 1,500,808,136.01 from CNY 1,336,143,759.93 at the beginning of the year, representing a growth of 12.3%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,499,765,833.99, representing a 2.75% increase from ¥12,165,124,976.56 at the end of the previous year[3] - The total assets of the company reached CNY 12,499,765,833.99, an increase from CNY 12,165,124,976.56 at the beginning of the year, marking a growth of 2.7%[20] - The total liabilities increased to CNY 3,622,045,879.06 from CNY 3,390,566,493.65, representing a rise of 6.8%[20] Shareholder Information - The top shareholder, Cheng Xianfeng, holds 40.23% of the shares, amounting to 496,526,307 shares[10] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 1.65% of the shares, totaling 20,370,446 shares[10] - Cheng Xianfeng and several investment funds are identified as acting in concert, indicating a coordinated shareholder strategy[12] - The top ten shareholders hold a total of 124,131,577 shares of common stock, representing a significant portion of the company's equity[11] Operating Costs and Expenses - The company's gross profit margin decreased due to a shift in revenue structure, with a 40.76% reduction in operating costs to ¥427,472,846.50 from ¥721,608,037.10[8] - Total operating costs for Q1 2022 were CNY 815,202,981.81, down 23.5% from CNY 1,065,298,825.32 in Q1 2021[21] - Financial expenses surged by 388.98% to ¥21,742,252.26, primarily due to increased interest expenses and foreign exchange losses[8] - Research and development expenses for Q1 2022 were CNY 38,302,629.24, slightly down from CNY 40,513,368.64 in the previous year[21] Product Development and Licensing - The company received drug registration certificates for multiple products, including Ammonium Bromide Injection on January 7, 2022[14] - The company signed an exclusive licensing agreement for the product F-627 with Apogepha Arzneimittel GmbH, involving a non-refundable advance of $400,000 and potential milestone payments up to $37.5 million[17] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., received a registration acceptance notice for Dopamine Hydrochloride Injection on January 11, 2022[14] - The company’s subsidiary, Liao Ning Yifan Pharmaceutical Co., received a registration acceptance notice for Tirofiban Hydrochloride Injection on January 24, 2022[14] - The company’s subsidiary, Yifan You Sheng Mei Te Pharmaceutical Technology Co., passed the consistency evaluation for Cefuroxime Sodium Injection[15] Stock and Incentives - The company has initiated a stock incentive plan, with the second vesting period approved on January 4, 2022[13] - Basic earnings per share for Q1 2022 were ¥0.10, compared to ¥0.11 in Q1 2021, reflecting a decrease of 9.1%[23] - The weighted average return on net assets was 1.41%, down from 1.55% in the previous year[3] - The company recorded other comprehensive income after tax of approximately -¥14.91 million, worsening from -¥3.69 million in the previous year[22]